ABSTRACT
Background Following the mass recall of valsartan products with nitrosamine impurities in July 2018, the number of patients exposed to these valsartan products, the duration of exposure, and the potential for cancer remains unknown. Therefore, we assessed the extent and duration of use of valsartan products with a nitrosamine impurity in the US, Canada, and Denmark.
Methods We conducted a retrospective cohort study using administrative healthcare data from the US FDA Sentinel System, four Canadian provinces that contribute to the Canadian Network for Observational Drug Effect Studies (CNODES), and the Danish National Prescription Registry. Patients, 18 years and older between May 2012 and December 2020 with a valsartan dispensing were identified in each database. Patients were followed from the date of valsartan dispensing until discontinuation. We defined four valsartan exposure categories based on nitrosamine impurity status; recalled generic products with confirmed NDMA/NDEA levels (recalled-tested); recalled generic products that were not tested (recalled); non-recalled generic and non-recalled branded products. In Denmark, recalled-tested category was not included due to absence of testing data. The proportion and duration of use of valsartan episodes stratified by nitrosamine-impurity status.
Results We identified 3.3 and 2.8 million (US) and 51.3 and 229 thousand (Canada) recalled-tested and recalled valsartan exposures. In Denmark, where valsartan exposure was generally low, there were 10,747 recalled exposures. Immediately after the recall notices were issued, there was increased rates of switching to a non-valsartan ARB. The mean duration of use of the recalled-tested products was 167(±223.1) and 146(±255.8) days in the US and Canada respectively. For the recalled products, mean cumulative duration of use was 178(±249.6), 269(±397.3) and 166(±251.0) days in the US, Canada, and Denmark, respectively.
Conclusion In this cohort study, despite widespread use of recalled generic valsartan between 2012 and 2018, the duration of use was relatively short and likely did not pose an elevated risk of nitrosamine-induced cancer. However, since products with nitrosamine impurity could have been on the market over a six-year period, patients potentially exposed to these products for longer duration could have a different risk of cancer.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable, the study is an observational retrospective study.
Funding Statement
The Canadian Network for Observational Drug Effect Studies (CNODES) is a core network partner of CoLab and funded by Canadian Agency for Drugs and Technologies in Health, CADTH (Grant #C222 360). At the time of this study CNODES was a collaborating center of the Drug Safety and Effectiveness Network (DSEN) and funded by the Canadian Institutes of Health Research (CIHR; Grant # DSE-146021). This study was made possible through data sharing agreements between the participating CNODES member research centers and the respective provincial governments of Manitoba, Nova Scotia, Ontario, and Saskatchewan. This project was supported by Task Order 75F40119F19002 under Master Agreement 75F40119D10037 from the U.S. Food and Drug Administration (FDA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study conducted in the FDA's Sentinel System is a public health surveillance activity conducted under the authority of the FDA and, accordingly, is not subject to Institutional Review Board oversight.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data cannot be shared with external stakeholders due to confidentiality agreements.
